Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia
Status:
Withdrawn
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
This phase II clinical trial is studying how well lenalidomide works in treating patients
with high-risk chronic lymphocytic leukemia. Biological therapies, such as lenalidomide, may
stimulate the immune system in different ways and stop cancer cells from growing.